InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,667.20
(
0.64%
)
US TECH 100
19,827.19
(
-0.09%
)
Dow Jones
40,954.48
(
1.85%
)
Brent Oil
83.26
(
-1.29%
)
Bitcoin
65,058.98
(
0.32%
)
Post# of 252610
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120055
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 193850

Tuesday, 07/28/2015 6:09:24 PM

Tuesday, July 28, 2015 6:09:24 PM

Post# of 252610
Re: GILD’s next-gen HCV programs

GILD’s GS-5816 is now called Velpatasvir; it is being tested in a 3-DAA regimen with Sovaldi and GS-9857 (a new protease inhibitor) in all HCV genotypes. Phase-2 data on 6-, 8-, and 12-week durations are expected in late 2015 (see slide #9 at the link in #msg-115759654).

Phase-3 data on the 2-DAA Sovaldi + Velpatasvir regimen for GT3 are expected during the current quarter.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up